Hepatic surgery-related hypophosphatemia

Clinica Chimica Acta

Volumn 380, Issue 1-2, 2007, Pages 13-23

  Datta, Harish K ^a,b   Malik, Mahdi ^a   Neely, R Dermot G ^a,b  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Hypophosphatemia; Liver; Metabolic stress; Nucleotide metabolism; Phosphatonins

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; FRIZZLED PROTEIN; GLYCOPROTEIN; NUCLEOTIDE; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATONIN DERIVATIVE; UNCLASSIFIED DRUG; VITAMIN D;

DISEASE SEVERITY; HUMAN; HYPOPHOSPHATEMIA; KIDNEY DISEASE; LIVER REGENERATION; LIVER SURGERY; LIVER TRANSPLANTATION; METABOLIC STRESS; NUCLEOTIDE METABOLISM; PATHOGENESIS; PATHOPHYSIOLOGY; PHOSPHATURIA; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN ISOLATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; REVIEW; URINALYSIS;

ANIMALS; HEPATECTOMY; HOMEOSTASIS; HUMANS; HYPOPHOSPHATEMIA; INTESTINAL ABSORPTION; LIVER DISEASES; LIVER TRANSPLANTATION; PHOSPHATES; POSTOPERATIVE COMPLICATIONS;

EID: 33947713045     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2007.01.027     Document Type: Review

References (123)

1. White S.A., Al-Mukhtar A., Lodge J.P., and Pollard S.G. Progress in living donor liver transplant. Transplant. Proc. 36 (2004) 2720-2726
2. George R., and Shiu M.H. Hypophosphataemia after major hepatic resection. Surgery 111 (1992) 281-286
3. Cohen J., Kogan A., Sahar G., Lev S., Vidne B., and Singer P. Hypophosphatemia following open heart surgery: incidence and consequences. Eur J Cardiothorac Surg 26 (2004) 306-310
4. Burak K.W., Rosen C.B., Fidler J.L., et al. Hypophosphataemia after right hepatectomy for living donor liver transplantation. Can J Gastroenterol 18 (2004) 729-733
5. Buell S.E., Berger A.C., Polkin J.S., Kuo P.S., and Johnson L.B. The clinical implications of hypophosphatemia following major hepatic resection or cryosurgery. Arch Surg 133 (1998) 757-761
6. Gaasbeek A., and Meinders A.E. Hypophosphataemia: an update on its aetiology and treatment. Am J Med 10 (2005) 1094-1101
7. Charron T., Bernard F., Skrobik Y., Simoneau N., Gagnon N., and Leblank M. Intravenous phosphate in the intensive care unit: More aggressive treatment for moderate hypophosphataemia. Intensive Care Med 8 (2003) 1273-1278
8. Vannatta J.B., Andress D.L., Wang R., and Papper S. High dose intravenous phosphorus therapy for severe, complicated hypophosphatemia. South Med J 76 (1983) 1424-1426
9. Tucker S.B., and Schimmel E.M. Postoperative hypophosphatemia: a multifactorial problem. Nutr Rev 47 (1989) 111-116
10. Portale A.A., Halloran B.P., and Morris Jr. R.C. Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men. J Clin Invest 83 (1989) 1494-1499
11. Nowicki M., Kokot F., and Surdacki A. The influence of hyperinsulinaemia on calcium-phosphate metabolism in renal. Nephrol Dial Transplant 13 (1998) 2566-2571
12. Estepa J.C., Aguilera-Tejero E., Lopez I., Almaden Y., Rodriguez M., and Felsenfeld A.J. Effect of phosphate on parathyroid hormone secretion in vivo. J Bone Miner Res 14 (1999) 1848-1854
13. Minutolo R., Bellizzi V., Cioffi M., et al. Postdialytic rebound of serum phosphorus: pathogenetic and clinical insights. J Am Soc Nephrol 13 (2002) 1046-1054
14. Ambuhl P.M., Meier D., Wolf B., Dydak U., Boesiger P., and Binswanger U. Metabolic aspects of phosphate replacement therapy for hypophosphatemia after renal transplantation: impact on muscular phosphate content, mineral metabolism, and acid/base homeostasis. Am J Kidney Dis 34 (1999) 875-883
15. Eicher E.M., Southard J.L., Scriver C.R., and Glorieux F.H. Hypophosphatemia: mouse model for human familial hypophosphatemic (vitamin D-resistant) rickets. Proc Natl Acad Sci U S A 73 (1976) 4667-4671
16. Meyer Jr. R.A., Meyer M.H., and Gray R.W. Parabiosis suggests a humoral factor is involved in X-linked hypophosphatemia in mice. J Bone Miner Res 4 (1989) 493-500
17. Cai Q., Hodgson S.F., Kao P.C., et al. Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med 330 (1994) 1645-1649
18. Econs M.J., and Drezner M.K. Tumor-induced osteomalacia-unveiling a new hormone. N Engl J Med 330 (1994) 1679-1681
19. Chalew S.A., Lovechild J.C., Brown C.M., and Sun C.-C.J. Hypophosphatemia induced in mice by transplantation of a tumor-derived cell line from a patient with oncogenic rickets. J Pediatr Endocrinol Metab 9 (1996) 593-597
20. White K.E., Larsson T.E., and Econs M.J. The roles of specific genes implicated as circulating factors involved in normal and disordered phosphate homeostasis: frizzled related protein-4, matrix extracellular phosphoglycoprotein, and fibroblast growth factor 23. Endocr Rev 27 (2006) 221-241
21. Qurales L.D. Evidence for a bone-kidney axis regulating phosphate homeostasis. J Clin Invest 112 (2003) 642-646
22. Schiavi S.C., and Kumar R. The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int 65 (2004) 1-14
23. Rowe P.S. The wrickkened pathways of FGF23, MEPE and PHEX. Crit Rev Oral Biol Med 15 (2004) 264-281
24. Econs M.J., McEnery P.T., Lennon F., and Speer M.C. Autosomaldominant hypophosphatemic rickets is linked to chromosome 12p13. J Clin Invest 100 (1997) 2653-2657
25. The ADHR Consortium. Autosomal dominant hypophosphatemicrickets is associated with mutations in FGF23. Nat Genet 26 (2000) 345-348
26. Shimada T., Mizutani S., Muto T., et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 98 (2001) 6500-6505
27. Folpe A.L., Fanburg-Smith J.C., Billings S.D., et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 28 (2004) 1-30
28. Larsson T., Zahradnik R., Lavigne J., Ljunggren O., Juppner H., and Jonsson K.B. Immunohistochemical detection of FGF-23 protein in tumors that cause oncogenic osteomalacia. Eur J Endocrinol 148 (2003) 269-276
29. Riminucci M., Collins M.T., Fedarko N.S., et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112 (2003) 83-92
30. Yan X., Yokote H., Jing X., et al. Fibroblast growth factor 23 reduces expression of type IIa Na+/Pi co-transporter by signaling through a receptor functionally distinct from the known FGFRs in opossum kidney cells. Genes Cells 10 (2005) 489-502
31. Ward L.M., Rauch F., White K.E., et al. Resolution of severe, adolescent-onset hypophosphatemic rickets following resection of an FGF-23-producing tumour of the distal ulna. Bone 34 (2004) 905-911
32. Murer H., Hernando N., Forster I., and Biber J. Proximal tubular phosphate reabsorption: molecular mechanisms. Physiol Rev 80 (2000) 1373-1409
33. Wikvall K. Cytochrome P450 enzymes in the bioactivation of vitamin D to its hormonal form. Int J Mol Med 7 (2001) 201-209
34. Shimada T., Hasegawa H., Yamazaki Y., et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19 (2004) 429-435
35. Yu X., Sabbagh Y., Davis S.I., Demay M.B., and White K.E. Genetic dissection of phosphate- and vitamin D-mediated regulation of circulating Fgf23 concentrations. Bone 36 (2005) 971-977
36. Ferrari S.L., Bonjour J.P., and Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 90 (2005) 1519-1524
37. Shimada T., Yamazaki Y., Takahashi M., et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 289 (2005) F1088-F1095
38. Burnett S.A., Gunawardene S.C., Bringhurst F.R., Juppner H., Lee H., and Finkelstein J.S. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 21 (2006) 1187-1196
39. Yu X., Sabbagh Y., Davis S.I., Demay M.B., and White K.E. Genetic dissection of phosphate- and vitamin D-mediated regulation of circulating Fgf23 concentrations. Bone 36 (2005) 971-977
40. Perwad F., Azam N., Zhang M.Y., Yamashita T., Tenenhouse H.S., and Portale A.A. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 146 (2005) 5358-5364
41. Mirams M., Robinson B.G., Mason R.S., and Nelson A.E. Bone as a source of FGF23: regulation by phosphate?. Bone 35 (2004) 1192-1199
42. Shimada T., Kakitani M., Yamazaki Y., et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113 (2004) 561-568
43. Yamashita H., Yamazaki Y., Hasegawa H., et al. Fibroblast growth factor-23 in patients with Graves' disease before and after antithyroid therapy: its important role in serum phosphate regulation. J Clin Endocrinol Metab 90 (2005) 4211-4215
44. Ito M., Sakai Y., Furumoto M., et al. Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells. Am J Physiol Endocrinol Metab 288 (2005) E1101-E1109
45. Inoue Y., Segawa H., Kaneko I., et al. Role of the vitamin D receptor in FGF23 action on phosphate metabolism. Biochem J 390 (2005) 325-331
46. Collins M.T., Lindsay J.R., Jain A., et al. Fibroblast growth factor-23 is regulated by 1alpha,25-dihydroxyvitamin D. J Bone Miner Res 20 (2005) 1944-1950
47. Liu S., Tang W., Zhou J., et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17 (2006) 1305-1315
48. Kolek O.I., Hines E.R., Jones M.D., et al. 1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 289 (2005) G1036-G1042
49. Saito H., Maeda A., Ohtomo S., et al. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 280 (2005) 2543-2549
50. Yu X., Ibrahimi O.A., Goetz R., et al. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 146 (2005) 4647-4656
51. Kuro-o M., Matsumura Y., Aizawa H., et al. Mutation of the mouse Klotho gene leads to a syndrome resembling ageing. Nature 390 (1997) 745-751
52. Urakawa I., Yamazaki Y., Shimada T., et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444 (2006) 770-774
53. Garringer H.J., Fisher C., Larsson T.E., et al. The role of mutant UDP-N-acetyl-alpha-d-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis. J Clin Endocrinol Metab 91 (2006) 4037-4042
54. Benet-Pages A., Orlik P., Strom T.M., and Lorenz-Depiereux B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 14 (2005) 385-390
55. Larsson T., Davis S.I., Garringer H.J., et al. Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed. Endocrinology 146 (2005) 3883-3891
56. Araya K., Fukumoto S., Backenroth R., et al. A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab 90 (2005) 5523-5527
57. Miyamoto K., Ito M., Kuwahata M., Kato S., and Segawa H. Inhibition of intestinal sodium-dependent inorganic phosphate transport by fibroblast growth factor 23. Ther Apher Dial 9 (2005) 331-335
58. The PEX Consortium. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 11 (1995) 130-136
59. Francis F., Strom T.M., Hennig S., et al. Genomic organization of the human PEX gene mutated in X-linked dominant hypophosphatemic rickets. Genome Res 7 (1997) 573-585
60. Beck L., Soumounou Y., Martel J., et al. Pex/PEX tissue distribution and evidence for a deletion in the 3_region of the Pex gene in X-linked hypophosphatemic mice. J Clin Invest 99 (1997) 1200-1209
61. Ruchon A.F., Marcinkiewicz M., Siegfried G., et al. Pex mRNA is localized in developing mouse osteoblasts and odontoblasts. J Histochem Cytochem 46 (1998) 459-468
62. Sitara D., Razzaque M.S., Hesse M., et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 23 (2004) 421-432
63. Liu S., Zhou J., Tang W., Jiang X., Rowe D.W., and Quarles L.D. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 291 (2006) E38-E49
64. Liu S., Guo R., Simpson L.G., Xiao Z.S., Burnham C.E., and Quarles L.D. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 278 (2003) 37419-37426
65. Bowe A.E., Finnegan R., Jan de Beur S.M., et al. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 284 (2001) 977-981
66. White K.E., Carn G., Lorenz-Depiereux B., Benet-Page`s A., Strom T.M., and Econs M.J. Autosomal dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60 (2001) 2079-2086
67. Benet-Pages A., Lorenz-Depiereux B., Zischka H., White K.E., Econs M.J., and Strom T.M. FGF23 is processed by proprotein convertases but not by PHEX. Bone 35 (2004) 455-462
68. Imanishi Y., Inaba M., Nakatsuka K., et al. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 65 (2004) 1943-1946
69. Kazama J.J., Sato F., Omori K., et al. Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int 67 (2005) 1120-1125
70. Pande S., Ritter C.S., Rothstein M., et al. FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol 104 (2006) 23-32
71. Bhan I., Shah A., Holmes J., et al. Post-transplant hypophosphatemia: tertiary 'hyper-phosphatoninism'?. Kidney Int 70 (2006) 1486-1494
72. Rattner A., Hsieh J.C., Smallwood P.M., et al. A family of secreted proteins contains homology to the cysteine-rich ligand-binding domain of frizzled receptors. Proc Natl Acad Sci U S A 94 (1997) 2859-2863
73. Jones S.E., and Jomary C. Secreted frizzled-related proteins: searching for relationships and patterns. Bioessays 24 (2002) 811-820
74. Hsieh J.C., Kodjabachian L., Rebbert M.L., et al. A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature 398 (1999) 431-436
75. Wang H.Y., and Malbon C.C. Wnt-frizzled signaling to G-proteincoupled effectors. Cell Mol Life Sci 61 (2004) 69-75
76. Berndt T., Craig T.A., Bowe A.E., et al. Secreted frizzled related protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest 112 (2003) 785-794
77. De Beur S.M., Finnegan R.B., Vassiliadis J., et al. Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res 17 (2002) 1102-1110
78. Beck L., Karaplis A.C., Amizuka N., Hewson A.S., Ozawa H., and Tenenhouse H.S. Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities. Proc Natl Acad Sci U S A 95 (1998) 5372-5377
79. Tenenhouse H.S., Roy S., Martel J., and Gauthier C. Differential expression, abundance, and regulation of Na_-phosphate cotransporter genes in murine kidney. Am J Physiol 275 (1998) F527-F553
80. Berndt T.J., Bielesz B., Craig T.A., et al. Secreted frizzled-related protein-4 reduces sodium-phosphate co-transporter abundance and activity in proximal tubule cells. Pflugers Arch 451 (2006) 579-587
81. Rowe P.S., de Zoysa P.A., Dong R., et al. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 67 (2000) 54-68
82. Petersen D.N., Tkalcevic G.T., Mansolf A.L., Rivera-Gonzalez R., and Brown T.A. Identification of osteoblast/osteocyte factor 45 (OF45), a bone-specific cDNA encoding an RGD-containing protein that is highly expressed in osteoblasts and osteocytes. J Biol Chem 275 (2000) 36172-36180
83. Argiro L., Desbarats M., Glorieux F.H., and Ecarot B. Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone. Genomics 74 (2001) 342-351
84. Siggelkow H., Schmidt E., Hennies B., and Hufner M. Evidence of downregulation of matrix extracellular phosphoglycoprotein during terminal differentiation in human osteoblasts. Bone 35 (2004) 570-576
85. Liu H., Li W., Gao C., Kumagai Y., Blacher R.W., and DenBesten P.K. Dentonin, a fragment of MEPE, enhanced dental pulp stem cell proliferation. J Dent Res 83 (2004) 496-499
86. Nampei A., Hashimoto J., Hayashida K., et al. Matrix extracellular phosphoglycoprotein (MEPE) is highly expressed in osteocytes in human bone. J Bone Miner Metab 22 (2004) 176-184
87. Lu C., Huang S., Miclau T., Helms J.A., and Colnot C. Mepe is expressed during skeletal development and regeneration. Histochem Cell Biol 121 (2004) 493-499
88. MacDougall M., Simmons D., Gu T.T., and Dong J. MEPE/OF45, a new dentin/bone matrix protein and candidate gene for dentin diseases mapping to chromosome 4q21. Connect Tissue Res 43 (2002) 320-330
89. Schlesinger D.H., and Hay D.I. Complete covalent structure of statherin, a tyrosine-rich acidic peptide which inhibits calcium phosphate precipitation from human parotid saliva. J Biol Chem 252 (1977) 1689-1695
90. Long J.R., Dindot J.L., Zebroski H., et al. A peptide that inhibits hydroxyapatite growth is in an extended conformation on the crystal surface. Proc Natl Acad Sci U S A 95 (1998) 12083-12087
91. Wesson J.A., Johnson R.J., Mazzali M., et al. Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. J Am Soc Nephrol 14 (2003) 139-147
92. Ogbureke K.U.E., and Fisher L.W. Expression of SIBLINGs and their partner MMPs in salivary glands. J Dent Res 83 (2004) 664-670
93. Ogbureke K.U., and Fisher L.W. Renal expression of SIBLING proteins and their partner matrix metalloproteinases (MMPs). Kidney Int 68 (2005) 155-166
94. Liu S., Brown T.A., Zhou J., et al. Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia. J Am Soc Nephrol 16 (2005) 1645-1653
95. Bresler D., Bruder J., Mohnike K., Fraser W.D., and Rowe P.S. Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets. J Endocrinol 183 (2004) R1-R9
96. Guo R., Rowe P.S., Liu S., Simpson L.G., Xiao Z.S., and Darryl Quarles L.D. Inhibition of MEPE cleavage by Phex. Biochem Biophys Res Commun 297 (2002) 38-45
97. Rowe P.S., Kumagai Y., Gutierrez G., et al. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 34 (2004) 303-319
98. Toomes C., James J., Wood A.J., et al. Loss-of-function mutations in the cathepsin C gene result in periodontal disease and palmoplantar keratosis. Nat Genet 23 (1999) 421-424
99. Rowe P.S., Garrett I.R., Schwarz P.M., et al. Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP). Bone 36 (2005) 33-46
100. Jain A., Fedarko N.S., Collins M.T., et al. Serum levels of matrix extracellular phosphoglycoprotein (MEPE) in normal humans correlate with serum phosphorus, parathyroid hormone and bone mineral density. J Clin Endocrinol Metab 89 (2004) 4158-4161
101. Gowen L.C., Petersen D.N., Mansolf A.L., et al. Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem 278 (2003) 1998-2007
102. Jan de Beur S.M., Jain A., Khan M., and Fedarko N.S. Matrix extracellular phosphoglycoprotein (MEPE) fragments circulate in excess in patients with tumor-induced osteomalacia (TIO) and X linked hypophosphatemic rickets. J Bone Miner Res 19 (2004) S101
103. Laroche M., and Boyer J.F. Phosphate diabetes, tubular phosphate reabsorption and phosphatonins. Joint Bone Spine 72 (2005) 376-381
104. Salem R.R., and Tray K. Hepatic resection-related hypophosphatemia is of renal origin as manifested by isolated hyperphosphaturia. Ann Surg 241 (2005) 343-348
105. Guicciardi M.E., Deussing J., Miyoshi H., et al. Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J Clin Invest 106 (2000) 1127-1137
106. Hettleman B.D., Sabina R.L., Drezner M.K., Holmes E.W., and Swain J.L. Defective adenosine triphosphate synthesis. An explanation for skeletal muscle dysfunction in phosphate-deficient mice. J Clin Invest 72 (1983) 582-589
107. Hopkirk T.J., and Denton R.M. Studies on the specific activity of [gamma-32P]ATP in adipose and other tissue preparations incubated with medium containing [32P]phosphate. Biochim Biophys Acta 885 (1986) 195-205
108. Whelan J.M., and Bagnara A.S. Factors affecting the rate of purine ribonucleotide dephosphorylation in human erythrocytes. Biochim Biophys Acta 563 (1979) 466-478
109. Rasmussen A., Kimose H.H., Segel E., and Hessoy I. Postoperative and glucose-induced hypophosphatemia in relation to adenosine triphosphate and 2,3-diphosphoglycerate in erythrocytes. Acta Chir Scand 155 (1989) 81-87
110. Palmese S., Pezza M., and De Robertis E. Hypophosphataemia and metabolic acidosis. Minerva Anestesiol 71 (2005) 237-242
111. Young J.A., Lichtman M.A., and Cohen J. Reduced red cell 2,3-diphosphoglycerate and adenosine triphosphate, hypophosphatemia, and increased hemoglobin-oxygen affinity after cardiac surgery. Circulation 47 (1973) 1313-1318
112. Ambuhl P.M., Meier D., Wolf B., Dydak U., Boesiger P., and Binswanger U. Metabolic aspects of phosphate replacement therapy for hypophosphatemia after renal transplantation: impact on muscular phosphate content, mineral metabolism, and acid/base homeostasis. Am J Kidney Dis 34 (1999) 875-883
113. Jara A., Felsenfeld A.J., Bover J., and Kleeman C.R. Chronic metabolic acidosis in azotemic rats on a high-phosphate diet halts the progression of renal disease. Kidney Int 58 (2000) 1023-1032
114. Preston C.J., Noorwali A., Chaalla A., et al. Intracellular inorganic phosphate and ATP levels in human blood erythrocytes, leucocytes and platelets in normal subjects and in diseases associated with altered phosphate metabolism. Adv Exp Med Biol 151 (1982) 147-155
115. Verhoeven A.J., Marszalek J., and Holmsen H. Regulation of platelet AMP deaminase activity in situ. Biochem J 265 (1990) 267-275
116. Massen J.G., van der Vusse G.J., Work M., and Kootstra G. Nucleotides, nucleosides, and oxypurines in human kidney measured by use of reversed-phase HPLC. Clin Chem 34 (1988) 1087-1090
117. Larsen V.H., Waldau T., Gravesen H., and Siggaard-Andersen O. Erythrocyte 2,3-diphosphoglycerate depletion associated with hypophosphatemia detected by routine arterial blood gas analysis. Scand J Clin Lab Invest Suppl 224 (1996) 83-87
118. Taylor B.E., Huey W.Y., Buchman T.G., Boyle W.A., and Coopersmith C.M. Treatment of hypophosphatemia using a protocol based on patient weight and serum phosphorus level in a surgical intensive care unit. J Am Coll Surg 198 (2004) 198-204
119. Clark S., Sacks G., Dickerson R., Kudsk K., and Brown R. Treatment of hypophosphatemia in patients receiving specialized nutrition support using a graduated dosing scheme: results from a prospective clinical trial. Crit Care Med 23 (1995) 1504-1511
120. Vannatta J.B., Andress D.L., Whang R., et al. High dose intravenous phosphorus therapy for severe, complicated hypophosphatemia. South Med J 76 (1983) 1424-1426
121. Van den Berghe G. Science in medicine: how does blood glucose control with insulin save lives in intensive care?. J Clin Invest 114 (2004) 1187-1195
122. Lindholm L., Bengtsson A., Hansdottir V., Westerlind A., and Jeppsson A. Insulin (GIK) improves central mixed and hepatic venous oxygenation in clinical cardiac surgery. Scand Cardiovasc J 35 (2001) 347-352
123. Catherine C.M.N., Frumento R.J., Hardy M.A., et al. Randomized, double-blind comparison of lactated Ringer's solution and 0.9% NaCl during renal transplantation. Anesth Analg 100 (2005) 1518-1524